title: Recent developments in the treatment of alcoholic chronic pancreatitis.
abstract: Chronic pancreatitis is a progressive inflammatory condition characterized by repeated attacks of abdominal pain, and the destruction and fibrosis of the pancreatic parenchyma which causes to reduced exocrine and endocrine functions. Alcohol is the most common cause of chronic pancreatitis. Although abstinence is usually considered a prerequisite for successful treatment of alcoholic chronic pancreatitis, we often encounter patients who have repeated attacks from the compensated stage through the transitional stage. In alcoholic chronic pancreatitis, continued alcohol consumption causes changes in the digestive hormones and vagal nerve function that induce the pancreatic acinar cells to oversecrete protein, increasing the protein concentration and viscosity of the pancreatic juice. This induces protein sedimentation from the pancreatic juice and formation of protein plugs within the pancreatic duct, triggering repeated attacks of acute pancreatitis. The treatment of alcoholic chronic pancreatitis includes alleviation of symptoms, particularly abdominal pain, elimination of trigger factors, prevention of recurrence and disease progression, adjuvant therapies for pancreatic exocrine and endocrine failure. Recently, the main constituent proteins in these protein plugs have been identified, enabling trials of several therapies, such as the administration of secretin formulations and endoscopic removal. Bromhexine hydrochloride, a bronchial mucolytic, has an affinity for the pancreatic acinar cells, inducing them to secrete pancreatic juice of low viscosity. In this review, we summarize the most recent thoughts about alcoholic chronic pancreatitis, and the new treatments, and in particular, we present our findings concerning the efficacy of bromhexine hydrochloride in the treatment of this disease.
authors.affiliation: Third Department of Internal Medicine, Nara Medical University, Nara, Japan. tat-tyan@xa2.so-net.ne.jp
authors.forename: Tatsuhiro
authors.initials: T
authors.lastname: Tsujimoto
authors.forename: Hideto
authors.initials: H
authors.lastname: Kawaratani
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Yoshiji
authors.forename: Masahito
authors.initials: M
authors.lastname: Uemura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fukui
mesh_terms: D000437:Alcoholism / Q000503:physiopathology / Q000534:rehabilitation; D001964:Bromhexine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018450:Disease Progression; D004724:Endoscopy; D010188:Exocrine Pancreatic Insufficiency / Q000503:physiopathology / Q000628:therapy; D005768:Gastrointestinal Hormones / Q000502:physiology; D006801:Humans; D008019:Life Style; D010189:Pancreatic Juice / Q000502:physiology; D019512:Pancreatitis, Alcoholic / Q000503:physiopathology / Q000628:therapy*; D012008:Recurrence; D012633:Secretin / Q000008:administration & dosage; D014630:Vagus Nerve / Q000503:physiopathology; D014783:Viscosity
chemical_list: D005768:Gastrointestinal Hormones; D012633:Secretin; D001964:Bromhexine